MONCTON, NEW BRUNSWICK -- (Marketwired) -- 03/14/17 -- Organigram Holdings Inc. (TSX VENTURE: OGI)(OTCQB: OGRMF) ("Organigram" or the "Company") announces that it has issued an aggregate of 1,500,000 incentive stock options to Greg Engel, a director of the Company and the Company's Chief Executive Officer, at an exercise price of $2.36 per share.
In accordance with Mr. Engel's employment contract, (i) 266,666 of the Options shall vest on March 13, 2018; (ii) 266,667 of the Options shall vest on March 13, 2019; and (iii) 266,667 of the Options shall vest on March 13, 2020.
Additionally, 350,000 stock options shall vest upon the common shares of the Company trading at a price at or greater than $4.76/share; and, 350,000 stock options shall vest upon the common shares of the Company trading at a price at or greater than $7.14/share. In each instance, the common shares of the Company must trade at or greater than the price set forth above for a period of not less than 20 consecutive trading days.
All of the above-mentioned options have been granted pursuant to the Company's Stock Option Plan which has been previously approved by the Company's shareholders and the TSX Venture Exchange. In accordance with the Plan, all such options shall expire 10 years after issuance.
For more information visit www.organigram.ca.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations ("ACMPR").
In February 2017, Organigram was ranked in the top ten Clean Technology & Life Sciences Sector on the TSX Venture Exchange 50.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, crop yields - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Organigram Holdings Inc.
Ray Gracewood
Chief Commercial Officer
rgracewood@Organigram.ca
Organigram Holdings Inc.
Giselle Doiron
Director of Investor and Media Relations
(506) 801-8986
